Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Obesity · 2023-03 · 31 (3) · 703-715
DOI: 10.1002/oby.23673 ↗At a glance
Randomisierte kontrollierte Studie in Obesity, published online on 2023-01-18. Written by Sean Wharton and 10 co-authors. Institution: York University, McMaster University, and Wharton Weight Management Clinic, Burlington, Ontario, Canada. Major MEDLINE topics: Overweight, Eating. Cited 131 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Objective
This study evaluated the effect of once‐weekly semaglutide 2.4 mg on 2‐year control of eating.
Methods
In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks. A 19‐item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants. P values were not controlled for multiplicity.
Results
In participants completing the Control of Eating Questionnaire (semaglutide, n = 88; placebo, n = 86), mean body weight changes were −14.8% (semaglutide) and −2.4% (placebo). Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 ( p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 ( p < 0.05); and for hunger and fullness at week 20 ( p < 0.001). Improvements in craving domain scores were positively correlated with reductions in body weight from baseline to week 104 with semaglutide. At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05).
Conclusions
In adults with overweight/obesity, semaglutide 2.4 mg improved short‐ and longer‐term control of eating associated with substantial weight loss. image
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- York University, McMaster University, and Wharton Weight Management Clinic, Burlington, Ontario, Canada.
- Division of Medicine, University College London Centre for Obesity Research, University College London, London, UK.
- National Institute of Health Research, University College London Hospital Biomedical Research Centre, London, UK.
- Centre for Weight Management and Metabolic Surgery, University College London Hospital, London, UK.
- Novo Nordisk A/S, Søborg, Denmark.
- Unit of Clinical Nutrition, Policlinico University Hospital, Palermo, Italy.
ORCID profiles: Sean Wharton, Silvio Buscemi, Thomas A Wadden, W Timothy Garvey
Cite
APA
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Garvey, W. T. (2023). Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity, 31(3), 703-715. https://doi.org/10.1002/oby.23673
Vancouver
Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity. 2023;31(3):703-715. doi:10.1002/oby.23673
BibTeX
@article{Wharton2023,
author = {Wharton, Sean and Batterham, Rachel L and Bhatta, Meena and Buscemi, Silvio and Christensen, Louise N and Frias, Juan P and Jódar, Esteban and Kandler, Kristian and Rigas, Georgia and Wadden, Thomas A and Garvey, W Timothy},
title = {Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5},
journal = {Obesity},
year = {2023},
volume = {31},
number = {3},
pages = {703--715},
doi = {10.1002/oby.23673}
}
EUVIMED